Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more
Market Cap & Net Worth: Pharmicell (005690)
Pharmicell (KO:005690) has a market capitalization of $683.56 Million (₩1.00 Trillion) as of March 19, 2026. Listed on the KO stock exchange, this Korea-based company holds position #10763 globally and #257 in its home market, demonstrating a 12.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmicell's stock price ₩16680.00 by its total outstanding shares 60004014 (60.00 Million).
Pharmicell Market Cap History: 2015 to 2026
Pharmicell's market capitalization history from 2015 to 2026. Data shows growth from $172.73 Million to $683.56 Million (12.07% CAGR).
Pharmicell Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmicell's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Pharmicell's market cap is 0.01 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.05x
Pharmicell's market cap is 0.05 times its annual earnings
0.11x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $212.69 Million | $27.84 Billion | -$676.71 Million | 0.01x | N/A |
| 2017 | $233.59 Million | $25.20 Billion | -$39.20 Billion | 0.01x | N/A |
| 2018 | $499.96 Million | $28.35 Billion | -$12.68 Billion | 0.02x | N/A |
| 2019 | $347.93 Million | $32.48 Billion | $4.35 Billion | 0.01x | 0.08x |
| 2020 | $708.97 Million | $37.75 Billion | $5.24 Billion | 0.02x | 0.14x |
| 2021 | $534.80 Million | $51.81 Billion | $9.45 Billion | 0.01x | 0.06x |
| 2022 | $463.08 Million | $60.18 Billion | $8.26 Billion | 0.01x | 0.06x |
| 2023 | $248.75 Million | $56.23 Billion | $3.58 Billion | 0.00x | 0.07x |
| 2024 | $339.32 Million | $64.85 Billion | $6.33 Billion | 0.01x | 0.05x |
Competitor Companies of 005690 by Market Capitalization
Companies near Pharmicell in the global market cap rankings as of March 19, 2026.
Key companies related to Pharmicell by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pharmicell Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharmicell's market cap moved from $172.73 Million to $ 683.56 Million, with a yearly change of 12.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩683.56 Million | +14.80% |
| 2025 | ₩595.45 Million | +75.48% |
| 2024 | ₩339.32 Million | +36.41% |
| 2023 | ₩248.75 Million | -46.28% |
| 2022 | ₩463.08 Million | -13.41% |
| 2021 | ₩534.80 Million | -24.57% |
| 2020 | ₩708.97 Million | +103.77% |
| 2019 | ₩347.93 Million | -30.41% |
| 2018 | ₩499.96 Million | +114.04% |
| 2017 | ₩233.59 Million | +9.83% |
| 2016 | ₩212.69 Million | +23.13% |
| 2015 | ₩172.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Pharmicell was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $683.56 Million USD |
| MoneyControl | $683.56 Million USD |
| MarketWatch | $683.56 Million USD |
| marketcap.company | $683.56 Million USD |
| Reuters | $683.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.